UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia

European journal of pharmacology, 2015-09, Vol.763 (Pt A), p.38-47

2015

Volltextzugriff (PDF)

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Heart (British Cardiac Society), 2015-03, Vol.101 (5), p.356-362

2015

Volltextzugriff (PDF)

Inhibiting PCSK9 — biology beyond LDL control

Nature reviews. Endocrinology, 2019, Vol.15 (1), p.52-62

2019

Volltextzugriff (PDF)

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study

Journal of lipid research, 2016-04, Vol.57 (4), p.697-705

2016

Volltextzugriff (PDF)

New Drugs for Atherosclerosis

Canadian journal of cardiology, 2017-03, Vol.33 (3), p.350-357

2017

Volltextzugriff (PDF)

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Circulation (New York, N.Y.), 2020-06, Vol.141 (22), p.1829-1831

2020

Volltextzugriff (PDF)

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Circulation (New York, N.Y.), 2018-09, Vol.138 (13), p.1304-1316

2018

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Mayo Clinic proceedings, 2020-01, Vol.95 (1), p.77-89

2020

Volltextzugriff (PDF)

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

European journal of clinical pharmacology, 2021-10, Vol.77 (10), p.1473-1484

2021

Volltextzugriff (PDF)

PCSK9 inhibitors in clinical practice: Delivering on the promise?

Atherosclerosis, 2018-03, Vol.270, p.205-210

2018

Volltextzugriff (PDF)

Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program

Future cardiology, 2018-11, Vol.14 (6), p.433-442

2018

Volltextzugriff (PDF)

Moving Targets: Recent Advances in Lipid-Lowering Therapies

Arteriosclerosis, thrombosis, and vascular biology, 2019-03, Vol.39 (3), p.349-359

2019

Volltextzugriff (PDF)

Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower- Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial

Diabetes care, 2018-01, Vol.41 (1), p.112-119

2018

Volltextzugriff (PDF)

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

JAMA cardiology, 2019-11, Vol.4 (11), p.1067

2019

Volltextzugriff (PDF)

Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials

Current opinion in cardiology, 2018-05, Vol.33 (3), p.269-275

2018

Volltextzugriff (PDF)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia

BMC medicine, 2015-10, Vol.13 (1), p.258-258, Article 258

2015

Volltextzugriff (PDF)

Homozygous familial hypercholesterolaemia: light at the end of the tunnel

European heart journal, 2018-04, Vol.39 (14), p.1169-1171

2018

Volltextzugriff (PDF)

How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population

Diabetologia, 2017-07, Vol.60 (7), p.1271-1275

2017

Volltextzugriff (PDF)

Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study

European heart journal, 2016-03, Vol.37 (11), p.880-889

2016

Volltextzugriff (PDF)

Can we afford not to screen for FH?

European heart journal, 2017-06, Vol.38 (23), p.1840-1842

2017

Volltextzugriff (PDF)

Response to Comments on Santema et al. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower-Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care 2018;41:112–119

Diabetes care, 2018-04, Vol.41 (4), p.e62-e63

2018

Volltextzugriff (PDF)

Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study

Journal of clinical lipidology, 2022-05, Vol.16 (3), p.306-314

2022

Volltextzugriff (PDF)

Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs

Current opinion in lipidology, 2013-12, Vol.24 (6), p.459-466

2013

Volltextzugriff (PDF)

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study1

Journal of lipid research, 2016-04, Vol.57 (4), p.697-705

2016

Volltextzugriff (PDF)

Is additional hyperbaric oxygen therapy cost-effective for treating ischemic diabetic ulcers? Study protocol for the Dutch DAMOCLES multicenter randomized clinical trial?

Journal of diabetes, 2015-01, Vol.7 (1), p.125-132

2015

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(35)
magazinearticle
(1)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Inhibiting PCSK9 — biology beyond LDL control

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study

New Drugs for Atherosclerosis

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

PCSK9 inhibitors in clinical practice: Delivering on the promise?

Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program

Moving Targets: Recent Advances in Lipid-Lowering Therapies

Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower- Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials

PCSK9 inhibition: the way forward in the treatment of dyslipidemia

Homozygous familial hypercholesterolaemia: light at the end of the tunnel

How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population

Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study

Can we afford not to screen for FH?

Response to Comments on Santema et al. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower-Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care 2018;41:112–119

Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study

Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study1

Is additional hyperbaric oxygen therapy cost-effective for treating ischemic diabetic ulcers? Study protocol for the Dutch DAMOCLES multicenter randomized clinical trial?

Suchergebnisse filtern